SI3436054T2 - Stabilizirani neproteinski sestavki klostridijskih toksinov - Google Patents

Stabilizirani neproteinski sestavki klostridijskih toksinov

Info

Publication number
SI3436054T2
SI3436054T2 SI201730128T SI201730128T SI3436054T2 SI 3436054 T2 SI3436054 T2 SI 3436054T2 SI 201730128 T SI201730128 T SI 201730128T SI 201730128 T SI201730128 T SI 201730128T SI 3436054 T2 SI3436054 T2 SI 3436054T2
Authority
SI
Slovenia
Prior art keywords
clostridial toxin
stabilized non
toxin compositions
protein
protein clostridial
Prior art date
Application number
SI201730128T
Other languages
English (en)
Other versions
SI3436054T1 (sl
Inventor
Maurice Abiad
Bhas Dani
Evgenyi Shalaev
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59974865&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3436054(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of SI3436054T1 publication Critical patent/SI3436054T1/sl
Publication of SI3436054T2 publication Critical patent/SI3436054T2/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
SI201730128T 2016-09-13 2017-09-13 Stabilizirani neproteinski sestavki klostridijskih toksinov SI3436054T2 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394009P 2016-09-13 2016-09-13
EP17784058.4A EP3436054B2 (en) 2016-09-13 2017-09-13 Stabilized non-protein clostridial toxin compositions
PCT/US2017/051369 WO2018053004A2 (en) 2016-09-13 2017-09-13 Non-protein clostridial toxin compositions

Publications (2)

Publication Number Publication Date
SI3436054T1 SI3436054T1 (sl) 2020-01-31
SI3436054T2 true SI3436054T2 (sl) 2022-09-30

Family

ID=59974865

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201730125T SI3432916T1 (sl) 2016-09-13 2017-09-13 Stabilizirani ne-protein klostridijski toksin sestavki
SI201730128T SI3436054T2 (sl) 2016-09-13 2017-09-13 Stabilizirani neproteinski sestavki klostridijskih toksinov

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201730125T SI3432916T1 (sl) 2016-09-13 2017-09-13 Stabilizirani ne-protein klostridijski toksin sestavki

Country Status (27)

Country Link
US (10) US20190247476A1 (sl)
EP (4) EP3436054B2 (sl)
JP (3) JP7217700B2 (sl)
KR (5) KR102444230B1 (sl)
CN (3) CN109803672A (sl)
AU (3) AU2017327369A1 (sl)
BR (2) BR112019004935A2 (sl)
CA (2) CA3036095A1 (sl)
CL (1) CL2019000586A1 (sl)
CO (1) CO2019003630A2 (sl)
CY (2) CY1122263T1 (sl)
DK (2) DK3436054T4 (sl)
ES (2) ES2755815T3 (sl)
HR (1) HRP20191966T4 (sl)
HU (2) HUE046449T2 (sl)
IL (2) IL265109B2 (sl)
LT (1) LT3436054T (sl)
MX (2) MX2019002835A (sl)
PH (1) PH12019500501A1 (sl)
PL (2) PL3436054T5 (sl)
PT (2) PT3432916T (sl)
RS (1) RS59600B2 (sl)
RU (2) RU2762607C2 (sl)
SA (1) SA519401298B1 (sl)
SI (2) SI3432916T1 (sl)
TW (2) TWI773686B (sl)
WO (2) WO2018053021A1 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
MX2019002835A (es) * 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
JP7079984B2 (ja) 2018-07-28 2022-06-03 エクソコバイオ インコーポレイテッド エキソソームの凍結乾燥方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
MX2021002992A (es) * 2018-09-13 2021-11-12 Allergan Inc Composiciones de toxina clostridial y acido hialuronico.
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
UY38744A (es) * 2019-06-07 2020-12-31 Nestle Skin Health S A Tratamiento de líneas glabelares y líneas cantales laterales de moderadas a muy graves
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
WO2021231669A1 (en) * 2020-05-15 2021-11-18 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10960060B1 (en) * 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
KR102520625B1 (ko) 2019-10-18 2023-04-12 펜랜드 파운데이션 치료에 사용하기 위한 보톨리늄 독소
RU2746035C1 (ru) * 2020-06-30 2021-04-06 Государственное бюджетное учреждение Санкт-Петербургский научно-исследовательский институт скорой помощи им. И.И. Джанелидзе Способ купирования болевого синдрома после эндопротезирования молочных желез
WO2023287728A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
WO2024102345A1 (en) 2022-11-07 2024-05-16 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin

Family Cites Families (443)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891319A (en) 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
US4958257A (en) 1989-03-29 1990-09-18 Hughes Aircraft Company Heat conducting interface for electronic module
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
JPH07504662A (ja) * 1992-03-13 1995-05-25 ベアズレイ、テリー　アール． 免疫無防備状態の宿主における治療用途のための免疫促進剤
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
EP1147776B1 (en) * 1993-12-28 2010-12-15 Allergan, Inc. Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
ES2238969T3 (es) 1994-05-09 2005-09-16 William J. Binder Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas.
ES2138740T3 (es) 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5756468A (en) 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5556771A (en) 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
ES2198484T3 (es) 1995-06-06 2004-02-01 L. Bruce Pearce Composiciones y procedimientos mejorados para quimiodenervacion usando neurotoxinas.
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
DE69833059T3 (de) 1997-07-15 2014-12-18 The Regents Of The University Of Colorado, A Body Corporate Verwendung von Botulinumtoxin zur Behandlung von Harninkontinenz
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
CN1073626C (zh) 1997-10-18 2001-10-24 卫生部兰州生物制品研究所 A型肉毒结晶毒素的生产工艺及生产该毒素所需的冻干保护液
SE510813C2 (sv) 1997-12-08 1999-06-28 Arla Ekonomisk Foerening Bakteriestam av arten Lactobacillus Paracasei subsp. paracasei, sammansättning därav för användning i livsmedel, samt produkt innehållande stammen
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20050147690A1 (en) 1998-09-25 2005-07-07 Masters David B. Biocompatible protein particles, particle devices and methods thereof
ES2173678T3 (es) 1999-01-27 2002-10-16 Idea Ag Vacunacion no invasiva a traves de la piel.
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6573244B1 (en) 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
EP2267010B1 (en) 1999-08-25 2014-05-07 Allergan, Inc. Activatable recombinant neurotoxins
US20030180289A1 (en) 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
CA2388676A1 (en) 1999-10-13 2001-04-19 Chiron Corporation Method of obtaining cellular immune responses from proteins
IL149778A0 (en) 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
US6500436B2 (en) 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US20030138460A1 (en) 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP1398038B2 (en) 2000-02-08 2011-01-26 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6653062B1 (en) 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US6630330B1 (en) 2000-08-02 2003-10-07 Biopolo S.C.A.R.L. Ascorbic acid production from yeast
EE200300201A (et) 2000-10-31 2003-08-15 Boehringer Ingelheim Pharmaceuticals, Inc. Püranoonsete proteaasi inhibiitorite iseemulgeeruva kompositsiooni oraalne doos
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
ITUD20010002A1 (it) 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US20060134140A1 (en) 2001-04-12 2006-06-22 Dana Lasko Compositions and methods for treating tumor spreading
US9157875B2 (en) 2001-05-16 2015-10-13 Benjamin P. Warner Drug development and manufacturing
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
BR0314558A (pt) 2002-10-10 2005-08-09 Diversa Corp Proteases, ácidos nucléicos codificando as mesmas e processos para preparar e usar as mesmas
MXPA05004278A (es) 2002-10-25 2005-10-05 Foamix Ltd Espuma cosmetica y farmaceutica.
US20040086532A1 (en) 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2003287640A1 (en) 2002-11-12 2004-06-03 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20060002862A1 (en) 2002-12-17 2006-01-05 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
NZ540425A (en) 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
MXPA05007568A (es) 2003-01-16 2005-09-21 Acadia Pharm Inc Agonistas inversos del receptor selectivo de serotonina 2a/2c como terapeuticos para enfermedades neurodegenerativas.
US20060153876A1 (en) 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
CN1942588B (zh) 2003-03-05 2013-06-12 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US20040214753A1 (en) 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040204471A1 (en) 2003-03-20 2004-10-14 Pharmacia Corporation Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
EP1610808A4 (en) 2003-03-26 2011-04-06 Sudhir Paul COVALENT BINDING OF LIGANDS TO NUCLEOPHILIC PROTEINS UNDER GUIDANCE BY NONCOVALENT BINDING
US7341843B2 (en) 2003-04-11 2008-03-11 Allergan, Inc. Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
US7396535B2 (en) 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
TW200513280A (en) 2003-07-02 2005-04-16 Alza Corp Microprojection array immunization patch and method
DE10333317A1 (de) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
US20050042775A1 (en) 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
EP1660013A4 (en) 2003-08-26 2011-07-20 Gel Del Technologies Inc BIOMATERIAL AND PROTEIN BIOCOACERVATES, METHODS OF MAKING AND USING THEM
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
WO2005044366A2 (en) 2003-10-31 2005-05-19 Alza Corporation System and method for transdermal vaccine delivery
MXPA06005677A (es) 2003-11-21 2006-12-14 Johnson & Johnson Metodo y sistema de suministro transdermico de vacuna asistido por ultrasonido.
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
EP1691746B1 (en) 2003-12-08 2015-05-27 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
ES2409351T3 (es) 2003-12-23 2013-06-26 Infinity Discovery, Inc. Análogos de ansamicinas que contienen benzoquinona para el tratamiento de cáncer
CA2552754A1 (en) 2004-01-09 2005-08-04 Alza Corporation Frequency assisted transdermal agent delivery method and system
FR2865131B1 (fr) 2004-01-15 2007-08-24 Gattefosse Ets Sa Utilisation d'un extrait d'acmella oleracea pour son effet botox like dans une composition cosmetique anti-rides
DK1718756T3 (da) 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7674454B2 (en) 2004-03-06 2010-03-09 Innovata Limited Enzyme-prodrug therapy for prosthetic joint repair
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
JP2007530680A (ja) 2004-04-01 2007-11-01 アルザ・コーポレーシヨン インフルエンザワクチンの経皮デリバリーのための装置および方法
MX343109B (es) 2004-04-09 2016-10-25 Wyeth * Atenuacion sinergistica del virus de la estomatitis vesicular, vectores de los mismos y composiciones inmunogenicas de los mismos.
WO2005103303A2 (en) 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
US7875436B2 (en) 2004-05-05 2011-01-25 Pharmaleads Peptide substrates recognizable by a botulinum toxin A, BoNT/A and the use thereof
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
CA2566759A1 (en) 2004-05-19 2005-11-24 Alza Corporation Method and formulation for transdermal delivery of immunologically active agents
DE102004026152A1 (de) 2004-05-28 2005-12-15 Basf Ag Fermentative Herstellung von Feinchemikalien
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
CN1976751A (zh) 2004-06-28 2007-06-06 H.隆德贝克有限公司 释放化学物质的多孔物品
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006011966A1 (en) 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
ES2479515T3 (es) 2004-07-26 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Composición terapéutica con una neurotoxina botulínica
CA2575994A1 (en) 2004-08-04 2006-02-16 Allergan, Inc. Optimizing expression of active botulinum toxin type a
GB2419527A (en) 2004-10-28 2006-05-03 Ipsen Ltd Pharmaceutical composition containing botulinum neurotoxin
PL1776137T3 (pl) 2004-08-04 2015-03-31 Ipsen Biopharm Ltd Kompozycja farmaceutyczna zawierająca neurotoksynę botulinową
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060057165A1 (en) 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
MX2007003968A (es) 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
WO2006042149A2 (en) 2004-10-06 2006-04-20 Allergan, Inc. Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
US7205018B2 (en) 2004-10-07 2007-04-17 Next Proteins, Inc. Carbonated protein drink and method of making
BRPI0515825A (pt) 2004-11-02 2008-08-05 Gangagen Life Sciences Inc formulações de bacteriófagos estabilizadas
CA2598204C (en) 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Stabilized hme composition with small drug particles
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
AU2005311086B2 (en) 2004-12-01 2012-03-29 Allergan, Inc. Fusion proteins
AU2005311098B2 (en) 2004-12-01 2011-08-11 Allergan, Inc. Non-cytotoxic protein conjugates
US8192979B2 (en) 2005-01-03 2012-06-05 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful Botulinum toxin formulations
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
CA2556796C (en) 2005-03-03 2018-01-23 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
JP5190654B2 (ja) 2005-03-31 2013-04-24 国立大学法人広島大学 分子マーカーを用いた間葉系幹細胞の識別方法及びその利用
PT1869459E (pt) 2005-04-05 2010-08-10 Allergan Inc Ensaios fret à base de corantes lipofílicos para a actividade da toxina de clostrídeo
US20070029252A1 (en) 2005-04-12 2007-02-08 Dunson James B Jr System and process for biomass treatment
US20090214466A1 (en) 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
PT1896065E (pt) 2005-06-27 2011-08-31 Glaxosmithkline Biolog Sa Processo para a preparação de vacinas
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
CA2618974C (en) 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007035455A2 (en) 2005-09-16 2007-03-29 Merial Limited Stabilizers for freeze-dried vaccines
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
CN101175478A (zh) * 2005-10-06 2008-05-07 阿勒根公司 非蛋白稳定的梭菌毒素药物组合物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
WO2007044809A2 (en) 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP1960547A2 (en) 2005-12-08 2008-08-27 Novartis AG Effects of inhibitors of fgfr3 on gene transcription
AU2006334020B2 (en) 2005-12-30 2012-07-05 Mor Research Applications Ltd. Device and method for treating the anal sphincter
AU2007204755A1 (en) 2006-01-10 2007-07-19 Eugene J. Van Scott N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
BRPI0706947B8 (pt) 2006-01-24 2021-05-25 Ansun Biopharma Inc método de preparação de uma composição de micropartícula
CA2681668C (en) 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
EP2105500A1 (de) 2008-03-26 2009-09-30 Pharmazell GmbH Neue 12alpha-Hydroxysteroiddehydrogenasen, deren Herstellung und deren Verwendung
US7473559B2 (en) 2006-04-05 2009-01-06 Charles Lee Method for measuring the content of a botulinum toxin in a formulation
US7309602B2 (en) 2006-04-13 2007-12-18 Ambrozea, Inc. Compositions and methods for producing fermentation products and residuals
ITTO20060282A1 (it) 2006-04-14 2007-10-15 Univ Degli Studi Torino Mezzo di coltura e composizione farmaceutica per la rigenerazione del tessuto cartilagineo relativo procedimento relativi usi e prodotti
AU2007347781B2 (en) 2006-07-11 2013-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
EP2038298A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US9061025B2 (en) 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US8043845B2 (en) 2006-09-20 2011-10-25 American Sterilizer Company Sterilization indicator
EP2511844B1 (en) 2006-10-10 2015-08-12 XRpro Sciences, Inc. X-ray microscope
EP1917971A1 (en) 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
EP1921149A1 (en) 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8444991B2 (en) 2007-03-22 2013-05-21 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
EP1985276A1 (en) 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
EP2170400B1 (en) 2007-07-10 2012-07-25 Medy-Tox, INC. Pharmaceutical liquid composition of botulinum toxin with improved stability
EP2198007B1 (en) 2007-09-14 2017-10-25 Sanofi Pasteur Biologics, LLC Pharmaceutical compositions containing clostridium difficile toxoids a and b
US8486467B1 (en) 2007-09-20 2013-07-16 Albert G. Prescott Dermal filler and method of using same
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
CN101969971A (zh) 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
EP2222833A4 (en) 2007-11-30 2011-05-18 Univ California MAJOR MANUFACTURE OF ORGANIC COMPOUNDS USING METHYL HALOGENIDE TRANSFERASE EXPRESSIVE RECOMBINANT ORGANISMS
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
WO2009093104A2 (en) 2008-01-25 2009-07-30 B & T S.R.L Use of transesterified olive oil in the cosmetic field
AU2009210266B2 (en) 2008-01-31 2015-01-29 CureVac SE Nucleic acids comprising formula (NuGlXmGmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvants
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
SI2271670T1 (sl) 2008-03-14 2015-01-30 Allergan, Inc. Preizkusi aktivnosti serotipa A botulin toksina na podlagi imunosti
EP2271301A4 (en) 2008-03-27 2014-07-02 Agigma Inc METHODS AND COMPOSITIONS FOR THE DELIVERY OF AGENTS
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US9119866B2 (en) 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
KR101100866B1 (ko) 2008-04-14 2012-01-02 한국과학기술원 게놈 수준에서의 부탄올 생산 미생물의 대사 네트워크 모델 및 이를 이용한 부탄올 생성 미생물의 대사특성분석 및 결실 표적 스크리닝 방법
ES2543727T3 (es) 2008-04-30 2015-08-21 Xyleco, Inc. Procesamiento de biomasa
KR20090120222A (ko) 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANOEMULSION VACCINES
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
WO2010011597A2 (en) 2008-07-22 2010-01-28 Mayo Foundation For Medical Education And Research Treatment of obesity and related disorders
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
EP2998402A1 (en) 2008-10-17 2016-03-23 Joule Unlimited Technologies, Inc. Ethanol production by microorganisms
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
SG10201901089TA (en) 2008-11-10 2019-03-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
CA2746425C (en) * 2008-12-10 2016-05-03 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP2379059A4 (en) 2008-12-10 2012-10-31 Anhui Zhongren Technology Co Ltd COMPOSITION WITH CONTROLLED RELEASE
WO2010071817A2 (en) 2008-12-19 2010-06-24 Momenta Pharmaceuticals, Inc. Characterization of o-linked glycans
PL2379104T3 (pl) 2008-12-31 2018-07-31 Revance Therapeutics, Inc. Preparaty toksyny botulinowej do wstrzykiwania
US9744237B2 (en) 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
BRPI1008885B1 (pt) 2009-02-19 2021-09-28 Merz Pharma Gmbh & Co. Kgaa Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição
EP2406629B9 (en) 2009-03-13 2014-03-26 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
HUE038699T2 (hu) 2009-03-13 2018-11-28 Allergan Inc "A " szerotípusú botulinum toxin immunalapú aktivitási vizsgálatára használható sejtek
JP6140445B2 (ja) 2009-04-01 2017-05-31 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 血管の過敏反応と関連した皮膚状態を治療する方法および組成物
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
US20180027833A1 (en) 2009-04-24 2018-02-01 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
AU2010238667B2 (en) 2009-04-24 2014-10-30 Société des Produits Nestlé S.A. Shelf-stable fermented dairy products and methods of making same
US9539233B2 (en) 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
SG10201402054UA (en) 2009-05-05 2014-09-26 Muthiah Manoharan Lipid compositions
US9545360B2 (en) 2009-05-13 2017-01-17 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
HUE056773T2 (hu) 2009-06-10 2022-03-28 Arbutus Biopharma Corp Továbbfejlesztett lipid készítmény
WO2010146591A2 (en) 2009-06-18 2010-12-23 Rdd Pharma Ltd. Methods and devices for delivery of pharmaceutical agents within orifices of the body
ES2615281T3 (es) 2009-06-24 2017-06-06 Charles N.S. Soparkar Suplementación con cinc para aumentar la capacidad de respuesta al tratamiento con metaloproteasa
US20120107431A1 (en) 2009-06-30 2012-05-03 Dong Hyun Kim Cosmetic composition containing a rubus coreanus extract for diminishing skin wrinkles
AU2010265888A1 (en) 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US9458536B2 (en) 2009-07-02 2016-10-04 Sio2 Medical Products, Inc. PECVD coating methods for capped syringes, cartridges and other articles
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US8431360B2 (en) 2009-07-24 2013-04-30 The Regents Of The University Of California Methods and compositions for improving sugar transport, mixed sugar fermentation, and production of biofuels
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
WO2011028962A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody coformulations
BR112012005763B1 (pt) 2009-09-14 2020-06-09 Changhae Ethanol Co Ltd método de preparação para materiais bio-combustíveis
JP2013513394A (ja) 2009-12-15 2013-04-22 ストラトリー・アーゲー 希薄水溶液から有機成分を回収するための方法
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
US10471150B2 (en) 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
ES2732150T3 (es) 2010-01-20 2019-11-20 Urogen Pharma Ltd Material y método para tratar cavidades internas
US8916162B2 (en) 2010-02-20 2014-12-23 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
GB201004072D0 (en) 2010-03-11 2010-04-28 Turzi Antoine Process, tube and device for the preparation of wound healant composition
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
EP2575773A4 (en) 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
BRPI1002601E2 (pt) 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
CN103079666B (zh) 2010-07-30 2017-10-24 米迪缪尼有限公司 纯化活性多肽或免疫偶联物的方法
AU2011316111B2 (en) 2010-10-12 2015-05-28 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
WO2012055408A1 (en) 2010-10-27 2012-05-03 Quantibact A/S Capture of target dna and rna by probes comprising intercalator molecules
CN103314101B (zh) 2010-11-03 2016-05-18 加利福尼亚大学董事会 通过蛋白质生物质发酵的重组微生物的生物燃料和化学生产
FR2967913A1 (fr) 2010-11-29 2012-06-01 Vetalis Composition galenique adaptee a l'administration a un animal non-humain, utilisations de celle-ci et methodes associees
WO2012094163A1 (en) 2011-01-07 2012-07-12 Revance Therapeutics, Inc. Methods and kits for topical application, removal, and inactivation of therapeutic or cosmetic toxin compositions
KR20190014125A (ko) 2011-01-24 2019-02-11 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
DK2675474T3 (en) 2011-02-15 2019-04-23 Vaxiion Therapeutics Llc THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES
AU2012220564A1 (en) 2011-02-23 2013-08-29 Ams Research Corporation Drug releasing pelvic treatment system and method
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
BR112013023062B1 (pt) 2011-03-10 2022-01-18 Xeris Pharmaceuticals, Inc Solução estável para a injeção parenteral e método de fabricação da mesma
SG10202013124XA (en) 2011-03-31 2021-02-25 Medy Tox Inc Lyophilized preparation of botulinum toxin
US20140030241A1 (en) 2011-03-31 2014-01-30 Nestec S.A. Nutritional compositions for increasing arginine levels and methods of using same
GB2505148B8 (en) 2011-04-07 2016-12-07 Virdia Ltd Lignocellulose conversion processes and products
EP2696867A1 (en) 2011-04-12 2014-02-19 Nestec S.A. Nutritional compositions including branched chain fatty acids for improving gut barrier function
WO2012143405A1 (en) 2011-04-18 2012-10-26 Nestec S.A. Nutritional compositions having alpha-hica and alpha-ketoglutarate
SG194875A1 (en) 2011-05-08 2013-12-30 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
CN103781491A (zh) 2011-05-17 2014-05-07 索利吉尼克斯公司 热稳定性疫苗组合物及其制备方法
CN103974715A (zh) 2011-06-17 2014-08-06 哈洛齐梅公司 乙酰透明质酸降解酶的稳定制剂
US8586020B2 (en) 2011-06-30 2013-11-19 Korea Institute Of Science And Technology Poly(organophosphazene) composition for biomaterials
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US20130053792A1 (en) 2011-08-24 2013-02-28 Ablative Solutions, Inc. Expandable catheter system for vessel wall injection and muscle and nerve fiber ablation
KR20130022923A (ko) 2011-08-26 2013-03-07 삼성전자주식회사 가상 시점 합성 예측을 이용한 부호화/복호화 장치 및 부호화/복호화 방법
US11707408B2 (en) 2011-10-25 2023-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CA3119789A1 (en) 2011-10-27 2013-05-02 Massachusetts Institute Of Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CN103930595A (zh) 2011-11-11 2014-07-16 Sio2医药产品公司 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备
WO2013087918A1 (en) 2011-12-15 2013-06-20 Nestec S.A. Cohesive thin liquids to promote safe swallowing in dysphagic patients
JP2015501649A (ja) 2011-12-15 2015-01-19 ネステク ソシエテ アノニム 食塊の安全な嚥下を促進するための伸長粘度
EP2797622B1 (en) 2011-12-30 2016-10-12 Halozyme, Inc. Ph20 polypeptide variants, formulations and uses thereof
EP2634190A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
BR112014026149A2 (pt) 2012-04-26 2017-07-18 Adisseo France Sas método para a preparação de 2,4-ácido dihidroxibutírico (2,4-dhb) e microrganismo.
WO2014005039A2 (en) 2012-06-29 2014-01-03 Cytosorbents Corporation Methods of using polymers
CN106170582A (zh) 2012-07-03 2016-11-30 Sio2医药产品公司 药物包装的SiOx 阻隔物和涂布方法
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
JP6368306B2 (ja) 2012-07-31 2018-08-01 ネステク ソシエテ アノニム 炎症性腸疾患（ｉｂｄ）患者の筋骨格の健康を促進させるための栄養組成物
CA2880285C (en) 2012-08-05 2022-11-01 Absci, Llc Inducible coexpression system
US10980865B2 (en) 2012-08-10 2021-04-20 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
WO2014026161A1 (en) 2012-08-10 2014-02-13 Aquavit Pharmaceuticals, Inc. Vitamin supplement compositions for injection
WO2015020982A2 (en) 2013-08-04 2015-02-12 Aquavit Pharmaceuticals, Inc. Direct application system and method for the delivery of bioactive compositions and formulations
WO2019135244A2 (en) 2018-01-07 2019-07-11 Avraham Amir High-load microneedles and compositions for skin augmentation
FR2996855B1 (fr) 2012-10-16 2016-11-11 Lesaffre & Cie Souches de levures pour la production de biomasse sur un substrat comprenant un sucre en c5, leurs procedes d'obtention et utilisations de la biomasse produite
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
KR20180077343A (ko) 2012-11-21 2018-07-06 입센 바이오이노베이션 리미티드 단백질 가수분해 처리된 폴리펩티드의 제조방법
EP2922555A4 (en) 2012-11-26 2016-06-15 Borody Thomas J COMPOSITIONS FOR THE RESTORATION OF AN FECAL MICROBIOTE AND METHODS OF MAKING AND USING THEM
WO2014100853A1 (en) 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
KR20150105979A (ko) 2013-01-11 2015-09-18 임파서블 푸즈 인크. 코아세르베이트를 포함하는 비-낙농 치즈 모조물
US9956287B2 (en) 2013-02-06 2018-05-01 Perosphere Inc. Stable glucagon formulations
US9650608B2 (en) 2013-02-22 2017-05-16 Medivet America, Llc Activating adipose-derived stem cells for transplantation
US9662450B2 (en) 2013-03-01 2017-05-30 Sio2 Medical Products, Inc. Plasma or CVD pre-treatment for lubricated pharmaceutical package, coating process and apparatus
KR102211788B1 (ko) 2013-03-11 2021-02-04 에스아이오2 메디컬 프로덕츠, 인크. 코팅된 패키징
US9937099B2 (en) 2013-03-11 2018-04-10 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging with low oxygen transmission rate
AU2014244232B2 (en) 2013-03-13 2019-05-02 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
JP2016513966A (ja) 2013-03-15 2016-05-19 ニューサート サイエンシーズ， インコーポレイテッド サーチュイン活性化剤によるペットの処置
US9603799B2 (en) 2013-03-15 2017-03-28 Htd Biosystems Inc. Liposomal vaccine adjuvants and methods of making and using same
EP2986140A4 (en) 2013-03-15 2016-10-19 Nusirt Sciences Inc COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
US20140294788A1 (en) 2013-03-26 2014-10-02 Nestec S.A. Methods for enhancing muscle protein synthesis following concurrent training
EP2981249A4 (en) 2013-04-02 2016-11-23 Stc Unm MESOPOROUS ALAN NANOPARTICLES AS A UNIVERSAL PLATFORM FOR ADSORPTION, PRESENTATION, AND ADMINISTRATION OF ANTIGENS
US20160073650A1 (en) 2013-04-16 2016-03-17 Nestec S.A. Shelf-stable fermented dairy products and methods of making same
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
WO2014186754A2 (en) 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CN103257233B (zh) 2013-05-31 2015-08-05 南京祥中生物科技有限公司 一种同时可视化检测多种抗生素、非法添加剂及生物毒素的生物芯片及方法
SG11201510671SA (en) 2013-07-02 2016-01-28 Austrianova Singapore Pte Ltd A method of freeze-drying encapsulated cells, freeze-dried encapsulated cells, compositions containing freeze-dried encapsulated cells and uses of such cells and compositions
MX2016001881A (es) 2013-08-15 2016-08-03 Lallemand Hungary Liquidity Man Llc Metodos para la mejora de rendimiento y produccion de producto en un microorganismo a traves del reciclaje de glicerol.
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
CN103705913A (zh) * 2013-12-27 2014-04-09 柳州市工人医院 A型肉毒毒素在制备治疗雷诺综合征药物的应用
AU2015204088A1 (en) 2014-01-02 2016-07-21 Trelys, Inc Compositions and methods for biological production of amino acids in hydrogenotrophic microorganisms
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
BR112016017690A2 (pt) 2014-01-29 2017-08-08 Vyome Biosciences Pvt Ltd Tratamentos para acne resistente
KR102327754B1 (ko) 2014-02-06 2021-11-17 엑스에리스 파머수티클스, 인크. 안정한 펩티드 제형물 및 제조 방법
EP3104868A2 (fr) 2014-02-14 2016-12-21 Vesale Pharma Sa Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US9389162B2 (en) 2014-04-10 2016-07-12 City University Of Hong Kong Detection of analyte using coffee-ring effect
AU2015243380B2 (en) 2014-04-11 2020-05-14 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
EP3132022A4 (en) 2014-04-15 2017-12-13 Industrial Microbes, Inc. Synthetic methanotrophic and methylotrophic microorganisms
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
DK3137053T3 (da) * 2014-04-30 2020-09-07 Allergan Inc Formuleringer af biologiske lægemidler til intravesikal instillation
EP3149187B1 (en) 2014-05-30 2020-04-29 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US20170209389A1 (en) 2014-07-23 2017-07-27 Landy Toth Precision chemical ablation and treatment of tissues
CA2957790A1 (en) 2014-08-13 2016-02-18 Akeso Biomedical, Inc. Antimicrobial compounds and compositions, and uses thereof
WO2016029146A1 (en) 2014-08-22 2016-02-25 University Of Washington Specific inhibitors of methionyl-trna synthetase
WO2016048689A1 (en) 2014-09-23 2016-03-31 Avidas Pharmaceuticals Llc Delivery and induction of therapeutic agents and uses thereof
US10325685B2 (en) 2014-10-21 2019-06-18 uBiome, Inc. Method and system for characterizing diet-related conditions
US10366793B2 (en) 2014-10-21 2019-07-30 uBiome, Inc. Method and system for characterizing microorganism-related conditions
US10381112B2 (en) 2014-10-21 2019-08-13 uBiome, Inc. Method and system for characterizing allergy-related conditions associated with microorganisms
US10357157B2 (en) 2014-10-21 2019-07-23 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
US10410749B2 (en) 2014-10-21 2019-09-10 uBiome, Inc. Method and system for microbiome-derived characterization, diagnostics and therapeutics for cutaneous conditions
US9710606B2 (en) 2014-10-21 2017-07-18 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for neurological health issues
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR102014028009B1 (pt) 2014-11-10 2023-04-18 Universidade Federal De Pelotas Composições filmogênicas para bioadesivos anestésicos tópicos (bats) para liberação controlada de princípios ativos e bioadesivos anestésicos tópicos
GB201421013D0 (en) 2014-11-26 2015-01-07 Turzi Antoine New standardizations & medical devices for the preparation of platelet rich plasma (PRP) or bone marrow centrate (BMC)
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
SG11201704699YA (en) 2014-12-08 2017-07-28 JJSK R&D Pte Ltd Carrier molecule compositions and related methods
CA2972233A1 (en) 2014-12-26 2016-06-30 Conjugon, Inc. Methods and compositions for growth, storage, and use of bacterial preparations for wound and surface treatments
US11040022B2 (en) 2015-02-05 2021-06-22 William H. Cross, III Compositions and methods for pain relief
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA2979529A1 (en) 2015-03-13 2016-09-22 Evolve Biosystems, Inc. Compositions that metabolize or sequester free sugar monomers and uses thereof
BR112017020058A2 (pt) 2015-03-20 2018-06-05 Childrens Nat Medical Ct processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células.
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
WO2016172658A2 (en) 2015-04-23 2016-10-27 Kaleido Biosciences, Inc. Microbiome regulators and related uses thereof
KR20180026670A (ko) 2015-05-26 2018-03-13 어드박시스, 인크. 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도
PL3334440T3 (pl) 2015-08-11 2021-11-02 Akeso Biomedical, Inc. Kompozycje hamujące tworzenie biofilmu wspierające przyrost masy ciała u zwierząt gospodarskich
MA42667A (fr) 2015-08-20 2021-05-05 Genomatica Inc Compositions et systèmes multiplexés pour la transcription-traduction et la synthèse protéique couplées sans cellules et procédés pour les utiliser
WO2017051254A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
WO2017066121A1 (en) 2015-10-12 2017-04-20 Toth, Landy Controlled and precise treatment of cardiac tissues
CA3006247A1 (en) 2015-11-25 2017-06-01 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
EP3380126A4 (en) 2015-11-25 2019-07-24 LegoChem Biosciences, Inc. ANTIBODY-MEDICINAL CONJUGATES COMPRISING BRANCHED LINKS AND RELATED METHODS
KR20180079452A (ko) 2015-11-25 2018-07-10 주식회사 레고켐 바이오사이언스 자기-희생기를 포함하는 접합체 및 이의 제조방법
CN105363018B (zh) 2015-12-02 2019-08-30 南京碧迪可医药科技有限公司 一种硫肽环素的新用途
US10795976B2 (en) 2016-01-11 2020-10-06 Siemens Aktiengesellschaft Program randomization for cyber-attack resilient control in programmable logic controllers
MX2018008906A (es) 2016-01-21 2019-01-10 Selux Diagnostics Inc Metodos para pruebas rapidas de susceptibilidad antimicrobiana.
US20170209553A1 (en) 2016-01-22 2017-07-27 Transderm, Inc. Delivery of botulinum with microneedle arrays
BR112018015155A2 (pt) 2016-01-25 2018-12-26 Bio Rad Europe Gmbh métodos para determinação da presença ou ausência de um micro-organismo em uma amostra, para testar rapidamente uma matriz alimentar e um micro-organismo alvo, e, composição.
US11771752B2 (en) 2016-03-09 2023-10-03 Prime Bio, Inc. Composition for oral or nasal delivery of tetanus, diphtheria, and pertussis vaccine alone or in combination using neurotoxin associated proteins
CA3017521A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes
CA3016922A1 (en) 2016-03-16 2017-09-21 Spogen Biotech Inc. Fusion proteins, recombinant bacteria, and exosporium fragments for animal health and aquaculture
WO2017179775A1 (en) 2016-04-12 2017-10-19 Hugel Inc. Microstructure formulation techniques for botulinum toxin
MX2018012486A (es) 2016-04-12 2019-06-06 Illustris Pharmaceuticals Inc Composiciones para aplicacion topica de compuestos.
WO2017189614A1 (en) 2016-04-25 2017-11-02 uBiome, Inc. Method and system for characterizing skin related conditions
RS62832B1 (sr) 2016-05-27 2022-02-28 Ipsen Biopharm Ltd Tečna neurotoksin formulacija stabilizovana sa triptofanom ili tirozinom
WO2017210700A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
MX2019000075A (es) 2016-07-08 2019-05-02 Metabolic Explorer Sa Metodo para la produccion fermentativa de moleculas de interes por microorganismos que comprenden genes que codifican el sistema de fosfotransferasa de azucar (pts).
WO2018038585A1 (ko) 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
WO2018039318A1 (en) 2016-08-26 2018-03-01 Akina, Inc. Biodegradable polymer formulations for extended efficacy of botulinum toxin
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
US11554108B2 (en) 2016-08-29 2023-01-17 Xeropedix, Inc. Methods and compositions for treating cutaneous fungal infections
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
KR102463881B1 (ko) 2016-10-04 2022-11-07 (주)메디톡스 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법
JP2020500089A (ja) 2016-10-26 2020-01-09 オキシ ソリューションズ アーエス 調合物
WO2018083692A1 (en) 2016-11-01 2018-05-11 Tamar Levin Novel methods for modulating protein expression in microorganisms
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US20180147357A1 (en) 2016-11-29 2018-05-31 Amir Marashi Delivery method for preparation and administration of pharmaceutical compositions
US11040090B2 (en) 2016-12-08 2021-06-22 Prime Bio, Inc Botulinum neurotoxin compositions
WO2018112419A1 (en) 2016-12-15 2018-06-21 uBiome, Inc. Method and system for characterizing diet-related conditions
WO2018112138A1 (en) 2016-12-15 2018-06-21 Anavi Goffer Sharon Treatment of mental, movement and behavioral disorders
US20190343139A1 (en) 2016-12-27 2019-11-14 IMB Inc. Processing human milk for generating compositions of fortified human milk products
CN108322936B (zh) 2017-01-16 2023-06-02 中兴通讯股份有限公司 数据重传的方法及装置
US20190345436A1 (en) 2017-01-17 2019-11-14 White Dog Labs, Inc. Proteinic biomass preparation comprising a non-native organism of the clostridia class
US20200121739A1 (en) 2017-01-18 2020-04-23 Evelo Biosciences, Inc. Bacteria for treating cancer
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
KR101776659B1 (ko) 2017-02-27 2017-09-11 주식회사 쿼드메디슨 마이크로 니들 및 이의 제조방법
US11642319B2 (en) 2017-03-24 2023-05-09 The Regents Of The University Of Colorado Targeted nanogels for urinary bladder therapies
WO2018195097A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of California Engineered commensal bacteria and methods of use
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
US11221337B2 (en) 2017-05-11 2022-01-11 Immundiagnostik Ag Method and test kit for the quantitative determination of biomarkers in fecal samples
RU2734159C1 (ru) 2017-05-24 2020-10-13 ЭйТиДжиСи КО., ЛТД. Фармацевтическая композиция для лечения болевого синдрома в стопе, включающая ботулинический токсин и гиалуроновую кислоту, и способ лечения болевого синдрома в стопе с ее использованием
BR112019025402A2 (pt) 2017-05-31 2020-06-23 Allergan, Inc. Neurotoxina botulínica para tratamento de distúrbios associados a hiperatividade de melanócito e/ou melanina em excesso
FR3067928B1 (fr) 2017-06-23 2020-02-28 Fondation Mediterranee Infection Procede de conservation d'un echantillon de bacteries
CA3068292A1 (en) 2017-06-26 2019-01-03 Bonti, Inc. Clostridial neurotoxin formulations and use
BR112019028301A2 (pt) 2017-07-05 2020-07-14 Evelo Biosciences, Inc. composições e métodos para tratar câncer com o uso de bifidobacterium animalis ssp. lactis
EP3669377A1 (en) 2017-08-14 2020-06-24 Psomagen, Inc. Disease-associated microbiome characterization process
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
TW201919671A (zh) 2017-08-30 2019-06-01 美商微辰生命有限公司 用於治療尿布疹、香港腳、接觸性皮膚炎、出汗及體臭之氨氧化微生物
KR20200053531A (ko) 2017-09-08 2020-05-18 에벨로 바이오사이언시즈, 인크. 박테리아 세포외 소포
EP3679057A1 (en) 2017-09-08 2020-07-15 Evelo Biosciences, Inc. Extracellular vesicles from prevotella
WO2019051204A1 (en) 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER
RU2020110399A (ru) 2017-10-03 2021-11-09 Крититек, Инк. Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019075452A1 (en) 2017-10-13 2019-04-18 Evelo Biosciences, Inc. IDENTIFICATION OF BACTERIA FOR CANCER THERAPY
CA3082696A1 (en) 2017-11-13 2019-05-16 Extremochem, Lda. Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
JP2021502964A (ja) 2017-11-14 2021-02-04 エヴェロ バイオサイエンシズ，インコーポレーテッド ブラウティア（Ｂｌａｕｔｉａ）株を使用して疾患を処置するための組成物及び方法
EP3716768A4 (en) 2017-11-22 2021-08-25 Aobiome LLC TOPICAL USE AND ADMINISTRATION OF MICROORGANISMS OXIDIZING AMMONIA
US20210369599A1 (en) 2017-11-22 2021-12-02 Aobiome Llc Topical use and delivery of ammonia oxidizing microorganisms
CA3083953A1 (en) 2017-12-11 2019-06-20 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
CN108205008B (zh) 2017-12-28 2020-04-21 深圳大学 一种基于有机光电化学晶体管的毒素传感器及其制备方法
CA3088258A1 (en) 2018-01-24 2019-08-01 Omnigen Research, Llc Bacillus combination for administration to animals
WO2019152667A1 (en) 2018-01-31 2019-08-08 Evelo Biosciences, Inc. Compositions and methods for treating immune disorders using lachnospiraceae bacteria
AU2019217526A1 (en) 2018-02-06 2020-08-13 Evelo Biosciences, Inc. Compositions and methods for treating cancer and immune disorders using Veillonella bacteria
JP2021515088A (ja) 2018-02-06 2021-06-17 レゲン ラブ エスエー 架橋ヒアルロン酸及びｐｒｐ／ｂｍｃとの組み合わせ
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
WO2019166514A1 (en) 2018-02-28 2019-09-06 C-Lecta Gmbh Enzymatic in-situ fortification of food with functional carbohydrates
WO2019178055A1 (en) 2018-03-12 2019-09-19 Evelo Biosciences, Inc. Extracellular vesicles from burkholderia
WO2019174560A1 (zh) 2018-03-14 2019-09-19 必康生技（香港）有限公司 用于生物流体净化的组合物
WO2019178490A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using klebsiella oxytoca
WO2019178494A1 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating cancer and inflammation using tyzzerella nexilis
EP3764988A4 (en) 2018-03-15 2022-04-20 Adepthera LLC GEL-FORMING POLYPEPTIDES
WO2019178487A2 (en) 2018-03-15 2019-09-19 Evelo Biosciences, Inc. Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
US20190321427A1 (en) 2018-04-18 2019-10-24 G&S Laboratories, Inc. Compositions to Treat Anal Fissures
US11918611B2 (en) 2018-05-03 2024-03-05 Crigasseni Ag Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases
WO2019226599A1 (en) 2018-05-22 2019-11-28 Alkalidx, Inc. Diagnostics and treatments of anesthetic insensitive subjects
US11464858B2 (en) 2018-06-23 2022-10-11 University Of Wyoming Magnetic nanoparticle delivery system for pain therapy
MX2021002992A (es) 2018-09-13 2021-11-12 Allergan Inc Composiciones de toxina clostridial y acido hialuronico.

Also Published As

Publication number Publication date
HRP20191966T1 (hr) 2020-01-24
AU2017326253B2 (en) 2021-10-21
US10369190B2 (en) 2019-08-06
CA3036095A1 (en) 2018-03-22
PL3432916T3 (pl) 2020-04-30
EP3436054B2 (en) 2022-07-27
US20230355724A1 (en) 2023-11-09
EP3639848A2 (en) 2020-04-22
CN117959415A (zh) 2024-05-03
CN109803672A (zh) 2019-05-24
PL3436054T5 (pl) 2023-01-30
RU2762607C2 (ru) 2021-12-21
DK3432916T3 (da) 2019-11-11
KR20240023684A (ko) 2024-02-22
US20230355723A1 (en) 2023-11-09
RU2019110875A (ru) 2020-10-15
CY1122263T1 (el) 2020-11-25
PT3432916T (pt) 2019-11-20
EP3626259A1 (en) 2020-03-25
IL308091A (en) 2023-12-01
KR20230004945A (ko) 2023-01-06
CO2019003630A2 (es) 2019-06-28
JP2019526611A (ja) 2019-09-19
EP3432916B1 (en) 2019-08-14
IL265109A (sl) 2019-04-30
EP3432916A1 (en) 2019-01-30
IL265109B2 (en) 2024-05-01
AU2021282546A1 (en) 2022-01-06
KR102480965B1 (ko) 2022-12-26
WO2018053004A3 (en) 2018-04-26
LT3436054T (lt) 2019-11-25
EP3639848A3 (en) 2020-12-16
US20210290739A1 (en) 2021-09-23
US20190247476A1 (en) 2019-08-15
PL3436054T3 (pl) 2020-06-15
ES2755816T3 (es) 2020-04-23
RS59600B2 (sr) 2022-10-31
MX2019002835A (es) 2019-09-04
KR20190053884A (ko) 2019-05-20
US20210369821A1 (en) 2021-12-02
SI3432916T1 (sl) 2020-01-31
IL265109B1 (en) 2024-01-01
RS59600B1 (sr) 2020-01-31
AU2017326253A1 (en) 2019-04-11
HUE046449T2 (hu) 2020-03-30
CL2019000586A1 (es) 2019-07-26
RU2019110875A3 (sl) 2021-01-12
PH12019500501A1 (en) 2019-05-27
TW201822786A (zh) 2018-07-01
US20240252604A1 (en) 2024-08-01
AU2017327369A1 (en) 2019-05-02
KR102635959B1 (ko) 2024-02-14
CY1122276T1 (el) 2020-11-25
DK3436054T3 (da) 2019-11-11
KR20220132013A (ko) 2022-09-29
BR112019004935A2 (pt) 2019-06-04
KR102444230B1 (ko) 2022-09-19
SI3436054T1 (sl) 2020-01-31
EP3436054B1 (en) 2019-08-14
RU2019110912A3 (sl) 2020-11-30
WO2018053004A2 (en) 2018-03-22
EP3436054A2 (en) 2019-02-06
US10973890B2 (en) 2021-04-13
US20230173041A1 (en) 2023-06-08
US20190351034A1 (en) 2019-11-21
TWI773686B (zh) 2022-08-11
JP2022179500A (ja) 2022-12-02
BR112019004929A2 (pt) 2019-06-04
PT3436054T (pt) 2019-11-19
DK3436054T4 (da) 2022-08-29
KR102558892B1 (ko) 2023-07-21
SA519401298B1 (ar) 2021-12-21
JP2019526609A (ja) 2019-09-19
HRP20191966T4 (hr) 2022-09-16
JP7217700B2 (ja) 2023-02-03
HUE046290T2 (hu) 2020-02-28
ES2755816T5 (es) 2022-10-24
WO2018053021A1 (en) 2018-03-22
US20180071361A1 (en) 2018-03-15
MX2023004911A (es) 2023-05-16
ES2755815T3 (es) 2020-04-23
US20240299509A1 (en) 2024-09-12
KR20190053214A (ko) 2019-05-17
RU2019110912A (ru) 2020-10-15
CA3035473A1 (en) 2018-03-22
TW202247855A (zh) 2022-12-16
CN109803673A (zh) 2019-05-24

Similar Documents

Publication Publication Date Title
SI3432916T1 (sl) Stabilizirani ne-protein klostridijski toksin sestavki
IL262575B (en) Chimeric neurotoxins
ZA201805110B (en) Fuel compositions
GB201621111D0 (en) Neurotoxins
IL265609A (en) New formulations
GB201607918D0 (en) Novel formulations
SG11201710212UA (en) Uv-blocking cosmetic composition
IL263714A (en) depot preparations
ZA201807392B (en) Fuel compositions
GB201717826D0 (en) Sunscreen compositions
PL3463259T3 (pl) Kompozycje przeciwsłoneczne
GB201616955D0 (en) Micro-milling
GB201619846D0 (en) Saponin composition
EP3440406B8 (en) Improved thermostat
GB2550950B (en) Puppet
AU201616517S (en) Sofa
GB201617866D0 (en) Novel formulations
GB201616509D0 (en) Novel formulations
AU201612338S (en) Lounge
GB201610195D0 (en) Puppet
GB201601612D0 (en) Nutritional composition
GB201512958D0 (en) Sunscreen compositions
GB201504894D0 (en) Sunscreen compositions
GB201504893D0 (en) Sunscreen compositions
GB201504892D0 (en) Sunscreen compositions